Program
TSL2109
A development code. Also written as “Treatment arm: TSL2109 capsules。Oral administration。”.
Its studies are mostly in Prostatic Neoplasms, led by China Resources Pharmaceutical Group.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| China Resources Pharmaceutical Group | 11 open or running | phase 1since Feb 25, 2026 | Feb 25, 2026 | Dec 31, 2026phase 1 · NCT07514065 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Feb 25, 2026First study: phase 1 study in Metastatic Castration-Resistant Prostate Cancer PatientsFirst studyNCT07514065 · 78 planned · China
Ahead
- Dec 31, 2026Primary completion: phase 1 study in Metastatic Castration-Resistant Prostate Cancer PatientsNCT07514065
TargetBeta
“TSL2109 is a novel CDK4/6-DYRK2 dual-target inhibitor developed by Jiangsu Tasly Diyee Pharmaceutical Co., Ltd.”study text, by rule · the study
Other programs on CDK4
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| abemaciclibrule | Eli Lilly | phase 4 | 49 |
| palbociclibrule | Pfizer | phase 4 | 36 |
| trilaciclibrule | Pharmacosmos | phase 4 | 14 |
| atirmociclib | Pfizer | phase 3 | 17 |
| culmerciclib | Sino Biopharmaceutical | phase 3 | 11 |
| HRS-6209 | Jiangsu HengRui Medicine | phase 3 | 7 |
| CDK4 Inhibitor BGB-43395rule | BeOne Medicines | phase 3 | 4 |
| narazaciclibrule | hangzhou-hanx-biopharmaceuticals-ltd | phase 2 | 4 |
| vustanaciclib | regor-pharmaceuticals-inc | phase 2 | 3 |
| CG-7321rule | chengdu-cynogen-bio-pharmaceutical-tech-co-ltd | phase 1 | 1 |
| nkt5097 cdk2rule | nikang-therapeutics-inc | phase 1 | 1 |
Studies
All 1 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07514065Metastatic Castration-Resistant Prostate Cancer Patients · China | 1 | Recruiting | Dec 31, 2026 | 78 |
How it is read
Names in the registry
- “Treatment arm: TSL2109 capsules。Oral administration。”, 1 entry
Codes read as this program: TSL2109.
Conditions, from the studies’ own filings
- Prostatic Neoplasms, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.